Abstract: The disclosure relates to immunological compositions (immunostimulants) based on nanoparticles as carrier for adjuvants, optionally in combination with antigens or epitopes, in particular for the use of the compositions for immunoprophylaxis or immunotherapy.

Abstract: The disclosure relates to a fusion protein comprising at least a first and a second peptide, wherein —the second peptide comprises a targeting region and a first and a second interaction region, —the second peptide is located on the surface of the fusion protein; —the second peptide comprises at least two interaction pairs, wherein an interaction pair is formed by an amino acid of the first interaction region and an amino acid of the second interaction region, —the interaction between the amino acids of an interaction pair is covalent or non-covalent; and —at least one interaction pair is a covalent interaction pair in which the amino acids are covalently bound, and to virus like particles (VLP) comprising the fusion protein for use as drug delivery system. Also provided are polynucleotides encoding the fusion protein, suitable expression vectors, host cells, production methods for the fusion protein and the VLP comprising the fusion protein.

Abstract: A method of using a virus-like particle from a polyomavirus having a first nucleic acid as a cargo to detect a second nucleic acid. The method includes providing the virus-like particle from the polyomavirus having the first nucleic acid as the cargo, and detecting, via the virus-like particle from the polyomavirus, the second nucleic acid.

Abstract: The present invention relates to a polypeptide consisting of or comprising a variant of human trypsinogen-1, comprising the substitutions: amino acid residue E64 is replaced with an amino acid residue comprising a positively charged side chain, amino acid residue K123 is replaced with an amino acid residue comprising an aliphatic side chain and amino acid residues Y139 and D147 are replaced with a glutamine or asparagine residue, and wherein said variant is further characterized in that: an amino acid residue selected from E16, E17 and E142 is replaced with an amino acid residue comprising an aliphatic side chain, and/or amino acid residue N18 is replaced with a histidine residue, and/or amino acid residue R107 is replaced with a lysine residue, and/or amino acid residue D138 is replaced with an amino acid residue comprising a positively charged side chain, and wherein said variant is cleavable into a polypeptide having a native-like enzymatic activity when compared to human trypsin-1.

Abstract: The disclosure relates to a fusion protein comprising at least a first and a second peptide, wherein —the second peptide comprises a targeting region and a first and a second interaction region, —the second peptide is located on the surface of the fusion protein; —the second peptide comprises at least two interaction pairs, wherein an interaction pair is formed by an amino acid of the first interaction region and an amino acid of the second interaction region, —the interaction between the amino acids of an interaction pair is covalent or non-covalent; and —at least one interaction pair is a covalent interaction pair in which the amino acids are covalently bound, and to virus like particles (VLP) comprising the fusion protein for use as drug delivery system. Also provided are polynucleotides encoding the fusion protein, suitable expression vectors, host cells, production methods for the fusion protein and the VLP comprising the fusion protein.